Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
TRAIL-induced HCC cell engraftment is enhanced by rocaglamide. HepG2 and H-7 cell engraftment were 9% and 11%, respectively, after rocaglamide therapy alone. HepG2 and H-7 cell engraftment was 16% and 17%, respectively, after TRAIL treatment. However, it is evident that the combination of Rocaglamide and TRAIL did more than just have an additive effect because it also generated cellular tolerance in 55% of HepG2 and 57% of Huh-7 cells. Injection violet staining was used to measure cell viability, and similar results were achieved. Highly drug- and chemoresistant HepG2 and Huh-7 cells may become more susceptible to TRAIL-based therapy when exposed to rocamide [2].
|
---|---|
ln Vivo |
Compared to the catalyst group, the tumor volume in the rocaramide-treated group was 45 ± 12%. When compared to catalyst, rocamide greatly slowed the growth of tumors. Rocamide was generally well tolerated, as evidenced by the fact that neither weight loss nor evident toxicity was seen consistently in mice during the treatment period in groups treated with the drug [2].
|
References |
[1]. Santagata S, et al. Tight coordination of protein translation and heat shock factor 1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341(6143): 1238303.
[2]. Luan Z, et al. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep [3]. Baumann B, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem. 2002 Nov 22;277(47):44791-800 |
Molecular Formula |
C29H31NO7
|
---|---|
Molecular Weight |
505.56
|
Exact Mass |
505.21005
|
CAS # |
84573-16-0
|
Related CAS # |
Aglafoline;143901-35-3;Didesmethylrocaglamide;177262-30-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O1C2C([H])=C(C([H])=C(C=2[C@@]2([C@@]([H])([C@]([H])(C(N(C([H])([H])[H])C([H])([H])[H])=O)[C@@]([H])(C3C([H])=C([H])C([H])=C([H])C=3[H])[C@]12C1C([H])=C([H])C(=C([H])C=1[H])OC([H])([H])[H])O[H])O[H])OC([H])([H])[H])OC([H])([H])[H]
|
Synonyms |
RocA; Rocaglamide A; Rocaglamide
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~197.80 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (14.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 7.5 mg/mL (14.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 4.76 mg/mL (9.42 mM) (saturation unknown) in 5% DMSO + 95% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9780 mL | 9.8900 mL | 19.7800 mL | |
5 mM | 0.3956 mL | 1.9780 mL | 3.9560 mL | |
10 mM | 0.1978 mL | 0.9890 mL | 1.9780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.